✦ LIBER ✦

PCN30 A COST—UTILITY ANALYSIS MODEL FOR THE SECOND LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN MEXICO

✍ Scribed by I Contreras-Hernandez; J Mould-Quevedo; G Salinas-Escudero; J Tapia-Valencia; G Davila-Loaiza; J Garduño-Espinosa

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN101 Cost Effectiveness of Everolimus

✍ J. Mihajlović; P. Pechlivanoglou; A. Sabo; Z. Tomić; M.J. Postma 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

PCN46 PHARMACOECONOMIC EVALUATION OF SUN

✍ C Tenorio; J Vargas; P Rizo-Rios; O Flores-Gil; J Martínez-Fonseca; J Mould-Quev 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

PCN15 COST-EFFECTIVENESS OF NEW TARGETED

✍ EC Aiello; N Muszbek; E Richardet; A Lingua; C Charbonneau; E Remák 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

PCN36 A COST UTILITY ANALYSIS OF FIRST-L

✍ K Le Lay; L Riou França; S Avoinet; N Chemali; R Launois 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Second-line systemic therapy for the tre

✍ Kruck, Stephan ;Bedke, Jens ;Kuczyk, Markus A ;Merseburger, Axel S 📂 Article 📅 2012 🏛 Expert Reviews 🌐 English ⚖ 473 KB

PCN20 REAL LIFE TREATMENT DURATION OF SO

✍ A Hammerman; SH Klang; N Liebermann 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB